S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

Neuronetics Stock Price, News & Analysis (NASDAQ:STIM)

$1.89
-0.06 (-3.08%)
(As of 12/6/2023 ET)
Compare
Today's Range
$1.87
$1.99
50-Day Range
$1.05
$2.21
52-Week Range
$1.03
$6.95
Volume
46,913 shs
Average Volume
163,902 shs
Market Capitalization
$54.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Neuronetics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
402.6% Upside
$9.50 Price Target
Short Interest
Bearish
1.27% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.68mentions of Neuronetics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$3,443 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.13) to ($0.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

221st out of 957 stocks

Surgical & Medical Instruments Industry

26th out of 78 stocks


STIM stock logo

About Neuronetics Stock (NASDAQ:STIM)

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

STIM Stock Price History

STIM Stock News Headlines

Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Lithium Discovery So BIG You Can't Miss it, Even From Space
With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!
Board Member of Neuronetics Purchased $51K In Stock
Cannell Capital Now Owns 8.45% of Neuronetics
Cannell Capital LLC Reduces Stake in Neuronetics Inc
Neuronetics (STIM) Receives a Buy from JMP Securities
STIM - Neuronetics, Inc.
See More Headlines
Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STIM
Employees
211
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$12.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+402.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-37,160,000.00
Pretax Margin
-47.81%

Debt

Sales & Book Value

Annual Sales
$65.21 million
Book Value
$2.10 per share

Miscellaneous

Free Float
27,428,000
Market Cap
$54.68 million
Optionable
Not Optionable
Beta
2.03
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives















STIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STIM shares.
View STIM analyst ratings
or view top-rated stocks.

What is Neuronetics' stock price target for 2024?

2 analysts have issued 1-year price objectives for Neuronetics' shares. Their STIM share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 402.6% from the stock's current price.
View analysts price targets for STIM
or view top-rated stocks among Wall Street analysts.

How have STIM shares performed in 2023?

Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM shares have decreased by 72.5% and is now trading at $1.89.
View the best growth stocks for 2023 here
.

When is Neuronetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our STIM earnings forecast
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) posted its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.03. The business earned $17.88 million during the quarter, compared to the consensus estimate of $17.66 million. Neuronetics had a negative trailing twelve-month return on equity of 70.12% and a negative net margin of 47.81%.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics updated its fourth quarter 2023 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.00 million-$21.00 million, compared to the consensus revenue estimate of $19.76 million.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by many different institutional and retail investors. Top institutional investors include Cannell Capital LLC (9.80%), Kent Lake Capital LLC (8.05%), First Eagle Investment Management LLC (2.69%), Acadian Asset Management LLC (1.28%), Millrace Asset Group Inc. (0.82%) and Blair William & Co. IL (0.32%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends
.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:STIM) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -